| Compound | Mazdutide |
|---|---|
| Category | GLP-1 / glucagon dual agonist |
| Class | GLP-1 and Incretin Therapies |
| Evidence tier | Clinical-stage |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
Mazdutide — a glp-1 / glucagon dual agonist — sits in the "Clinical-stage" tier of this catalog. This compound has completed or is undergoing formal human trials. Human safety and efficacy are being characterized, but no universal approval exists and results may still fail or be withdrawn.
A once-weekly GLP-1/glucagon dual receptor agonist developed primarily in China for weight management and type 2 diabetes. Phase 3 trials are in progress; it is not yet an approved medicine.
Mechanism of Action
Mazdutide activates both the GLP-1 receptor and the glucagon receptor, pairing appetite suppression with proposed glucagon-driven effects on energy expenditure and lipid metabolism.
Research and Evidence
Phase 2 dose-ranging studies in Chinese populations reported double-digit percentage weight reductions at higher doses, supporting progression to phase 3. Head-to-head comparisons with approved GLP-1 therapies are not yet available.
Safety and Side Effects
Available data indicate a gastrointestinal adverse-effect profile broadly consistent with the incretin class, with longer-term safety still being established in the registrational program.
Frequently Asked Questions
What is the evidence tier of Mazdutide?
Mazdutide is graded "Clinical-stage" on this site. This compound has completed or is undergoing formal human trials. Human safety and efficacy are being characterized, but no universal approval exists and results may still fail or be withdrawn.
Is Mazdutide an approved medicine?
No. Clinical-stage means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for Mazdutide?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — registered mazdutide studies. [source]
Evidence tier: Clinical-stage · Last reviewed: 2026-09-05 · Sources cited below.